CNL’S CNRI-H PROGRAM CONTINUES STRONG GROWTH THANKS TO NEW PROJECTS WITH REPARE THERAPEUTICS AND DEFENCE THERAPEUTICS ...

Repare and CNL plan to leverage the strengths of both organizations which cut across radiobiology, preclinical evaluation, ...

A downtrend has been apparent in Repare Therapeutics Inc. (RPTX) lately with too much selling pressure. The stock has declined 5.2% over the past four weeks. However, given the fact that it is now ...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology ...

Repare Therapeutics (RPTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts ...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced a Cooperative Research and Development Agreement ...

Canada’s national nuclear laboratories announces new projects with leading Canadian biopharmaceutical companies through collaborative research program ...

In a report released today, Charles Zhu from LifeSci Capital maintained a Hold rating on Repare Therapeutics (RPTX – Research Report). The company’s shares closed last Wednesday at $1.28.

16:11 EST Repare Therapeutics (RPTX) to seek partnering opportunities across portfolio Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline ...